Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: fewer (74), minus (30), excluding (249)

MyelomaBortezomib SC DexamethasonePabinostatThalidomide 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (SC)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day)
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-SC-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

MyelomaBortezomib SC DexamethasonePabinostat 28 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (SC)-DEXAMETHASONE-PANOBINOSTAT (28 day) Regimen • Multiple Myeloma – Bortezomi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-SC-DexamethasonePabinostat-28-day.pdf

Papers Trust Board - 27 July 2023

Description: Date Time Location Chair Agenda Trust Board – Open Session 27/07/2023 9:00 - 13:15 Conference Room, Heartbeat/Microsoft Teams
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Papers-Trust-Board-27-July-2023.pdf

Enhertu (trastuzumab deruxtecan)

Description: Chemotherapy Protocol BREAST CANCER ENHERTU (trastuzumab deruxtecan) ENHERTU is NOT the same drug as Kadcy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Enhertu-trastuzumab-deruxtecan.pdf

UHS AR 23-24 Final

Description: 2023/24 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2023/24 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-23-24-Final.pdf

Endometrial Carboplatin-Cisplatin-PaclitaxelRT(21day)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5)-CISPLATIN-PACLITAXEL RT Regimen • Endometrial-Carboplatin (AUC5)-Cispl
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Endometrial-Carboplatin-Cisplatin-Paclitaxel-RT-21day.pdf

Pembrolizumab 400mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (200mg) Regimen • Bladder – Pembrolizumab (200mg) Indication •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-200mg.pdf

Fulvestrant-Ribociclib

Description: Chemotherapy Protocol Breast Cancer Fulvestrant-Ribociclib Regimen • Breast Cancer – Fulvestrant-Ribociclib Ind
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Fulvestrant-Ribociclib.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description: Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuxima
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

21 to 30 of 1000

Previous 1 2 3 4 5 … Next